Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found no difference in CAG repeat length between Chinese and Australian men, refuting the hypothesis that this polymorphism and central prostate zone volume are markers of long-term androgen sensitivity.

This study found that Medicare patients with benign prostatic hyperplasia had high adherence to 5-alpha reductase inhibitor therapy, which was associated with a reduced risk of needing surgical intervention.

This study found that finasteride altered androgen receptor expression in the rat epididymis without affecting the morphology of epididymal epithelium, suggesting a change in hormonal status.

This study found that in non-obese women with moderate body hair growth, DHEA-S and prolactin levels were higher, and SBP was lower compared to controls, which may inform treatment decisions.

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

The effectiveness of finasteride for preventing chronic bacterial prostatitis is unclear.

This study suggests that the adrenal gland may contribute to prostate cancer treatment resistance and indicates potential steroid production or dependency in ovarian cancer.

This study found that treating dogs with benign prostatic hyperplasia using osaterone acetate reduced prostatic volume and increased diffusion times of an ultrasound contrast agent, suggesting effective treatment and potential for CEUS monitoring.

This study found that lower urinary tract symptoms in older men with benign prostatic hyperplasia negatively impact sexual function and mental health, suggesting the importance of early intervention to improve quality of life.

This study found that oral administration of finasteride to pregnant rats caused dosage-related developmental toxicities, including hypospadias and decreased anogenital distance in male offspring.

Finasteride is safe for long-term use in prostate cancer treatment.

The document aimed to understand how certain treatments affect blood vessel growth in rat prostates.

This study found that combining cyproterone acetate with testosterone enanthate was highly effective in suppressing spermatogenesis, suggesting potential as a reversible male contraceptive method.

In this study, estetrol (E4) treatment was associated with increased hair growth in ex vivo human hair follicles, suggesting its potential as a treatment for hair loss disorders.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

This study identified specific genes and pathways in human Leydig cells that may contribute to Post-finasteride Syndrome, potentially informing future treatments to reverse persistent side effects.

In this study, exposure to the drug finasteride in Silurana tropicalis significantly increased testosterone levels in liver and testis tissues and altered gene expression related to male reproduction and oxidative stress.

This study examined the effects of finasteride on human Leydig cells and found altered methylation in dopaminergic pathways, suggesting potential epigenetic contributions to post-finasteride syndrome, warranting further investigation.

In this study, researchers found that using a 5-α reductase inhibitor may reduce inflammation-related cytokines associated with T-helper cell 1 and T-helper cell 2 in prostate tissues after surgery, but it did not affect those related to Th17 cells.

This study found that finasteride improved urodynamic measures of obstruction in men with benign prostatic enlargement and lower urinary tract symptoms, with continued improvement over two years of treatment.

In this study, three cases of young men using finasteride for five years showed altered sperm morphology and motility issues, with partial improvement observed after discontinuation.

This study found no significant difference in urinary androgen and prostaglandin levels between male pattern baldness patients treated with finasteride for one year and normal controls.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This study found that a novel saw palmetto supercritical CO2 extract effectively inhibits 5α-reductase type II in vitro, suggesting its potential for promoting prostate health in benign prostatic hyperplasia.

This article discusses Fluxactive Complete, a natural supplement for prostate health, and reports no new clinical results.

This article reviews potential prevention and intervention strategies for prostate cancer, including 5alpha-reductase inhibition, but reports no new clinical findings.

This editorial comment discusses combination therapy for benign prostatic hyperplasia but presents no new research findings.